

VOL. 24, NO. 1, 1992

CODEN BCTRD6
ISSN 0167-6806

DEC 23 1992
HEALTH SCIENCES LIBRARY

Breast Cancer Research and Treatment

Marc E. Lippman, MD, editor-in-chief

Kluwer Academic Publishers

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

Breast Cancer Research and Treatment

Marc E. Lippman, M.D.¹ (Editor-in-Chief), Gary C. Chamness, Ph.D.²/Robert L. Dickson, Ph.D.¹ (Editors),
C. Kent Osborne, M.D.²/Gary M. Clark, Ph.D.² (Associate Editors)

¹*Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington DC, USA*

²*University of Texas Health Science Center at San Antonio, San Antonio TX, USA*

Editorial office address:

Karen S. Cullen, BREA Editorial Office, Kluwer Academic Publishers, 101 Philip Drive, Assinippi Park,
Norwell, MA 02061, USA; Tel: 617-871-6300; Fax: 617-871-6528; E-mail; Karen @ world. std. com.

EDITORIAL ADVISORY BOARD

George Blumenschein (Arlington, Texas)	Edwin Fisher (Pittsburgh, Pennsylvania)	Heinrich Maass (Hamburg, Germany)
Gianni Bonadonna (Milan, Italy)	Jan-Åke Gustafsson (Stockholm, Sweden)	Kenneth S. McCarty, Jr. (Durham, North Carolina)
Paul P. Carbone (Madison, Wisconsin)	Kathryn Horwitz (Denver, Colorado)	Daniel Medina (Houston, Texas)
Dean P. Edwards (Denver, Colorado)	Elwood V. Jensen (Hamburg, Germany)	Henri Rochefort (Montpellier, France)
Evert Engelsman (Amsterdam, The Netherlands)	V. Craig Jordan (Madison, Wisconsin)	Richard Santen (Hershey, Pennsylvania)
Bernard Fisher (Pittsburgh, Pennsylvania)	Roger King (London, United Kingdom)	Jeffrey Schlom (Bethesda, Maryland)
		Haruo Sugano (Tokyo, Japan)
		Jeffrey M. Trent (Tucson, Arizona)

Breast Cancer Research and Treatment is published monthly (1992).

Subscription prices for 1992, Volumes 21, 22, 23 and 24 (3 issues each) are:

For institutions Dfl. 960,00/US\$490.00 including postage and handling.

For individuals Dfl. 455,00/US\$245.00 including postage and handling.

Subscriptions should be sent to *Kluwer Academic Publishers Group, P.O. Box 322, 3300 AH Dordrecht, The Netherlands*, or at, *P.O. Box 358, Accord Station, Hingham, MA 02018-0358, U.S.A.*, or to any subscription agent. Private subscriptions should be sent direct to the publishers. Changes of mailing address should be notified together with our latest label.

For advertisement rates, prices of back volumes, and other information, please apply to Kluwer Academic Publishers, P.O. Box 17, 3300 AA Dordrecht, The Netherlands.

Photocopying. *In the U.S.A.:* This journal is registered at the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970.

Authorisation to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Kluwer Academic Publishers for users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of \$5.00 per copy is paid directly to CCC. For those organisations that have been granted a photocopy licence by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0167-6806/92/\$5.00.

Authorisation does not extend to other kinds of copying, such as that for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

In the rest of the world: Permission to photocopy must be obtained from the copyright owner. Please apply to Kluwer Academic Publishers, P.O. Box 17, 3300 AA Dordrecht, The Netherlands.

© 1992 Kluwer Academic Publishers

Breast Cancer Research and Treatment

Marc E. Lippman, M.D. ¹ (Editor-in-Chief), Gary C. Chamness, Ph.D. ² / Robert L. Dickson, Ph.D. ¹ (Editors),
C. Kent Osborne, M.D. ² / Gary M. Clark, Ph.D. ² (Associate Editors)

¹ *Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington DC, USA*

² *University of Texas Health Science Center at San Antonio, San Antonio, TX, USA*

Editorial office address:

Karen S. Cullen, BREA Editorial Office, Kluwer Academic Publishers, 101 Philip Drive, Assinippi Park,
Norwell, MA 02061, USA; Tel: 617-871-6300; Fax: 617-871-6528; E-mail: Karen@world.std.com.

EDITORIAL ADVISORY BOARD

George Blumenschein (Arlington,
Texas)

Gianni Bonadonna (Milan, Italy)

Paul P. Carbone (Madison,
Wisconsin)

Dean P. Edwards (Denver,
Colorado)

Evert Engelsman (Amsterdam, The
Netherlands)

Bernard Fisher (Pittsburgh,
Pennsylvania)

Edwin Fisher (Pittsburgh,
Pennsylvania)

Jan-Åke Gustafsson (Stockholm,
Sweden)

Kathryn Horwitz (Denver,
Colorado)

Elwood V. Jensen (Hamburg,
Germany)

V. Craig Jordan (Madison, Wisconsin)

Roger King (London, United Kingdom)

Heinrich Maass (Hamburg, Germany)

Kenneth S. McCarty, Jr. (Durham,
North Carolina)

Daniel Medina (Houston, Texas)

Henri Rochefort (Montpellier, France)

Richard Santen (Hershey,
Pennsylvania)

Jeffrey Schlom (Bethesda, Maryland)

Haruo Sugano (Tokyo, Japan)

Jeffrey M. Trent (Tucson, Arizona)

ISSN 0167-6806

All Rights Reserved

© 1992 by Kluwer Academic Publishers

No part of the material protected by this copyright notice may be reproduced or utilised in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage and retrieval system, without written permission from the copyright owner

Printed in The Netherlands

15th San Antonio Breast Cancer Symposium — Plenary lecture

The future of new pure antiestrogens in clinical breast cancer

Alan E. Wakeling

Bioscience I, ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom

Key words: breast cancer, antiestrogens, tamoxifen, resistance

Summary

The rationale for seeking to identify new pure antiestrogens was based on the recognition that existing antiestrogens, exemplified by tamoxifen, all possess partial agonist (estrogenic) activity. Conceptually, pure antiestrogens should be more effective than tamoxifen in ablating the mitogenic action of estrogens on breast tumor growth. The discovery and properties of the pure antiestrogens ICI 164,384 and ICI 182,780 are described and contrasted with those of tamoxifen. Key characteristics of these compounds which may be of particular relevance to their therapeutic application in the treatment of breast cancer are described. These include experimental data which predict efficacy in patients whose disease recurs during tamoxifen treatment, and the potential for pure antiestrogens to demonstrate greater efficacy than tamoxifen in first-line treatment of advanced breast cancer. The data imply that gains in efficacy could emerge as more rapid, more complete, or longer-lasting tumor remissions. Clinical trials with ICI 182,780 will reveal whether one or more of these predictions is correct.

Introduction

The nonsteroidal antiestrogen tamoxifen, ('Nolvadex'¹, ICI 46,474), is established as the treatment of choice for the endocrine therapy of advanced breast cancer [1]. Its ease of use and the absence of serious side effects in patients stimulated trials to assess the value of tamoxifen in adjuvant treatment of primary breast cancer [2,3] and, more recently, the initiation of trials to test its potential as a chemo-preventive agent in women at high risk of developing breast cancer [4,5]. The proportion of patients with advanced breast cancer

who respond to Nolvadex, and the average duration of response, are not significantly greater than those obtained with other endocrine treatments. Nolvadex treatment is palliative, and the majority of women who respond to treatment will experience relapse. In adjuvant therapy, Nolvadex extends the disease-free interval and overall survival compared with no treatment [3]. Current clinical practice in the adjuvant use of Nolvadex shows an increasing trend towards continuation of drug treatment until disease recurrence. These clinical observations pose several important questions about future directions for treatment,

Address for offprints and correspondence: Alan E. Wakeling, Bioscience I, ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom

¹ 'Nolvadex' is a Trade Mark, the property of Imperial Chemical Industries plc

two of which are considered here. Firstly, what treatment(s) should be applied in patients relapsing during or after Nolvadex treatment? Secondly, will pure antiestrogens provide more effective treatment of advanced breast cancer than Nolvadex or other currently available drug treatments? It will be argued that pure antiestrogens have particular properties which will provide answers to these important questions.

Rationale for pure antiestrogens

In early animal studies it was shown that tamoxifen antagonises the tropic actions of endogenous or exogenous estrogens but also, when administered alone to immature (or ovariectomised) rats and mice, itself has tropic (estrogenic) effects [6,7]. Thus, tamoxifen has the characteristics of an antiestrogen with partial agonist activity. In animals and in man the balance between stimulatory and inhibitory activities of tamoxifen varies widely depending on the organ, cell, or specific protein measured as an indicator of estrogenic activity [8,9]. Tamoxifen shares this property with chemically similar, triphenylethylene-derived agents, described earlier and more recently [10]. A consequence of this partial agonist activity is that *complete* blockade of the action of estrogens cannot be achieved with tamoxifen. Although it is not known whether the partial agonist activity of tamoxifen in any way limits its clinical efficacy, *complete* ablation of the estrogen-mediated tumor growth is a desirable objective since it might be anticipated to provide more rapid, more complete, or longer-lasting tumor responses. Conceptually, this objective could be achieved by treatment with a pure antiestrogen.

The profile of activity of a pure antiestrogen is easily understood in the pharmacological sense; developments in understanding the molecular mode of action of estrogens and how this is affected by tamoxifen, also facilitated a biochemical concept of how such agents might work.

Estrogens stimulate tumor growth by binding to estrogen receptors (ER) in the cell nucleus. The estrogen-ER complex then dimerizes and binds to specific DNA sequences (estrogen response elements, ERE), to activate the transcription of estrogen responsive genes which ultimately trigger cell proliferation. Tamoxifen disrupts this process by binding to ER and interfering with normal transcriptional responses to estrogens [11]. The estrogenic effects of tamoxifen strongly imply that the tamoxifen-receptor complex in the cell nucleus is not inert — it retains some capacity to transduce signals similar to those induced by the estrogen-ER complex [11]. In contrast it might be anticipated that pure antiestrogens should bind to ER to form an ER-complex which either does not bind to ERE's or, if DNA binding does occur, is unable to promote transcription.

Discovery of novel antiestrogens

The two key elements of the search for pure antiestrogens were, firstly, a medicinal chemistry strategy to identify novel ER ligands and, secondly, robust and reliable biological test systems. The strategy chosen for initial chemistry is described elsewhere [12] and involved synthesis of estradiol analogues bearing C7-substituents which retain a high affinity for ER, an essential feature recognized in our drug target profile [13]. Facile and reproducible testing for both estrogen agonist and antagonist activity *in vivo* was provided by measurement of uterotrophic and antiuterotrophic effects in immature rats [14]. In this assay, tamoxifen alone maximally increases the uterine weight 2-fold, compared with 5-fold for estradiol. Correspondingly, coadministration of tamoxifen and estradiol demonstrates a maximum 60% inhibition of the tropic action of estradiol. In addition to this bioassay, the intrinsic potency of new compounds could be monitored accurately *in vitro* by receptor binding measurements [15] and cell growth inhibition assays with estrogen-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.